Skip to main content
. 2019 Oct 25;21(6):108. doi: 10.1208/s12248-019-0378-y

Fig. 1.

Fig. 1

Cumulative percent dissolved (mean ± SD) versus time profiles for upadacitinib ER formulations containing 10% HPMC (formulation A), 15% HPMC (formulation B), 20% HPMC (formulation C; target formulation), and 35% HPMC (formulation D). F2 values comparing the four formulations are presented